MedPath

The Effect of Losartan and Amlodipine on Left Ventricular Diastolic Function in Patients With Mild-to-Moderate Hypertensio

Phase 4
Conditions
Hypertensive heart disease
Registration Number
JPRN-C000000319
Lead Sponsor
J-ELAN study group
Brief Summary

nder the similar reduction of blood pressure, losartan is likely effective in protecting the progression of atherosclerosis of the carotid artery compared to amlodipine. Losartan may improve LV diastolic function, and amlodipine may attenuate LV hypertrophy; however this study cannot make consecutive remarks about the superiority of either treatment regimen in the effects on cardiac function and geometry.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
300
Inclusion Criteria

Not provided

Exclusion Criteria

•History of a life-threatening adverse event induced by ARB or CCB •Pregnant woman •Serious liver dysfunction (aspartate aminotransferase or alanine aminotransferase more than 10 times of normal upper limit) •Serum creatinine > 1.8 mg/dl, known bilateral renal artery stenosis, single kidney, renal sclerosis •Secondary hypertension, malignant hypertension, hypertensive encephalopathy •Cardiovascular or cerebrovascular accidents within the last 6 months •Patients with angina pectoris who need CCB or beta-blocker •Significant aortic stenosis (peak transaortic valve pressure gradient > 20 mmHg) •Important aortic or mitral regurgitation in the investigators opinion •Patients with other diseases which affect the serum levels of carboxy-terminal telopeptide of collagen type I (CITP) and carboxy-terminal of procollagen type III (PIIIP) •Prescription of ACEI or ARB within 5 months •Prescription of beta-blocker or CCB within 4 weeks

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath